Just in 👉A comprehensive review of PARPi+ARPI combos in 1st line mCRPC #ProstateCancer 👇 by Rana McKay Alicia Morgans, MD, MPH neal shore et al. OPEN access link👉 tinyurl.com/4kajr2h3 OncoAlert UroToday.com PCF Science

ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team…

📣 Submit your abstract for #EMUC24 & get ready to access the latest advancements in #GUcancers

🔗 ow.ly/5lsS50Rf6eV

European Association of Urology (EAU) ESTRO

💫🌟 NCCN 2024 Prostate Cancer Guidelines Update 🌟💫
Zach Klaassen Rashid K. Sayyid
UroToday.com OncoAlert Advanced Prostate Cancer Consensus Conference urotoday.com/video-lectures…
🔹️ Major updates focus on the management of progressive M0 CSPC post-maximal pelvic therapy. 
🔹️ Introduction of enzalutamide, with or…

🗓️As the hybrid #APCCC24 swiftly approaches with its start date of April 25th, we're eager to revisit Session 2, focusing on the critical areas of Biochemical Recurrence and PSA Persistence in prostate cancer.

Derya Tilki and Thomas Zilli skillfully guide this session in Part…

Great summary of recently published European Urology article by Kent Mouw re use of SG / EV plus Radiation in bladder cancer . Listen below .. read here europeanurology.com/article/S0302-…

🚀 Excited to share our latest comprehensive review on Enzalutamide's role in primary and non-metastatic recurrent settings?

link.springer.com/article/10.103…

Dive into our publication where we dissect the evidence in this areas.

Vérane Achard Thomas Zilli Constantinos Zamboglou Christian D. Fankhauser

PEACE V – Salvage treatment of oligoRecurrent nodal #ProstateCancer metastases #STORM : 24-Months toxicity results of a randomized phase II trial. Presented by Thomas Zilli. #EAU24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/49wyX66 European Association of Urology (EAU)

4/n
Intention-to-treat:
6 mo pain reduction significantly improved in SBRT group vs cEBRT: 69.4% vs. 41.9% (p=0.02)

Per-protocol-analysis:
6 mo pain reduction significantly improved in SBRT group vs cEBRT: 78.1 vs. 43.3% (p=0.005)

DOSIS - RCT in pts with painful vertebral mets
Hypothesis: improved LC -> durable pain response
First randomized trial with 6 mo pain reduction as prim endpoint
N=63 pts randomized to SBRT vs conv. RT
Significant benefit of SBRT: 69.4% vs. 41.9% (p=0.02)
doi.org/10.1002/cncr.3…

📢 A randomized phase-III Trial Result:
⭐️Dose-intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases outperforms conventional external beam radiotherapy (cEBRT) in pain relief.
⏩SBRT group: 69.4% experienced pain reduction by 2 or more points at 6…

#EAU24 PEACE V-STORM: Ph 2 RCT of salvage MDT + 6 mo ADT +/- ENRT for Oligorecurrent nodal PCa: 24-mo toxicity results Thomas Zilli
UroToday.com

n=97, MDT vs n=93, ENRT
📌Worst late Gr ≥ 2 GI AEs: 5.3% vs 6.6% (p=0.94)
📌Worst late GU ≥ 2 GU AEs: 22.2% vs 26.5% (p=0.61)

Thomas Zilli presenting STORM 2-yr tox results. Efficacy results will be at #ESTRO24 in Glasgow!

EOC and IOSI playing a lead role at the most important Annual Urologic Meeting. At EAU Paris 2024, Ticino rulez!!!!

Superpower?
WE are the superpowered...
Congrats for this amazing meeting #EAU24
European Association of Urology (EAU)
Alberto Bossi Thomas Zilli

❓What timing for radiotherapy☢️after radical prostatectomy for prostate cancer?

Results of the RADICALS-RT randomized trial of adjuvant RT vs observation with salvage RT for PSA failure are published in Annals of Oncology

Matt Sydes @mrcctu @pcaparker
annalsofoncology.org/article/S0923-…

Open position at IOSI-EOC for a dosimetrist! recruitingapp-2761.umantis.com/Vacancies/2275…

MVDP on the Paterberg riding to victory 🤛

EORTC 2235 Radiotherapy for BCG–unresponsive Non–muscle-invasive Carcinoma In Situ Bladder Cancer: A need to be revisited. PI: Vérane Achard Paul Sargos Morgan Roupret EORTC EORTC_GUCG_YECI sciencedirect.com/science/articl…

Retrospective study NSCLC pts brain-only M+
- 103 pts: SRS of brain mets in all pts, definitive Tx of primary in 51%
- Local TX of primary associated with ⬆️ PFS & OS
- MVA for OS: definitive TX of primary, TX with IO, and AJCC stage
👏 Beaumont Radiation Oncology
thegreenjournal.com/article/S0167-…